Experts are leading an initiative to drive home the message that clinicians must consider MS in the differential diagnosis for Black patients and others who present with symptoms of demyelination.
Early progression independent of relapse activity is tied to poorer outcomes in multiple sclerosis (MS) and warrants reconsideration of how relapsing-remitting MS is classified, experts say.
Pheno Therapeutics Limited., a biotechnology company focused on the discovery and development of small molecule therapeutics that promote remyelination for the treatment of neurological diseases such as multiple sclerosis, announced today it has entered into an exclusive worldwide license agreement with UCB.
MIT research shows that in people carrying the APOE4 risk variant, a key brain cell type mismanages cholesterol needed to insulate neurons properly another sign that APOE4 contributes to Alzheimer's disease by disrupting lipids in the brain.